Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between August 14, 2026, and August 17, 2026. Valion Bio, Inc. (Nasdaq: VBIO), an emerging growth company incorporated in Delaware, reported significant corporate governance changes, a new financing tranche, and the results of a Special Meeting of Stockholders.
Key Financial Metrics and Capital Events
- Financing: Entered into a Letter Agreement with 3i, LP to issue 1,500 shares of Series B Preferred Stock and associated warrants for an aggregate purchase price of $1,500,000. Closing is expected on or about August 17, 2026.
- Royalty Obligation: Executed a Royalty Agreement requiring the Company to pay 3i and other purchasers 5% of the gross revenue of its wholly-owned subsidiary, Velocity Bioworks, Inc., from third parties for a period of 10 years.
- Capital Structure: As of the July 7, 2026 record date, there were 4,151,259 shares of common stock issued and outstanding. Preferred stockholders (Series A, B, and C) were not entitled to vote on the matters presented.
- Financial Statements: This filing does not provide specific revenue, profit, cash flow, or debt metrics for the period.
Material Changes and Corporate Actions
- Executive Leadership Changes:
- Termination: Michael K. Handley was terminated as Chief Executive Officer effective August 16, 2026.
- Appointment: Lisa Wolf was appointed Chief Operating Officer effective August 16, 2026, while retaining her role as Chief Financial Officer.
- Stockholder Vote Results: At the Special Meeting on August 14, 2026, approximately 46.75% of outstanding common stock was represented.
- Proposal 1 (Reverse Stock Split): Approved. Stockholders granted the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within 12 months. (Votes For: 1,243,030; Votes Against: 697,127).
- Proposal 2 (Adjournment): Approved, though the Chair did not elect to adjourn the meeting as Proposal 1 passed. (Votes For: 1,242,480; Votes Against: 686,908).
Outlook, Risks, and Contingencies
- Future Funding: The Company and 3i are negotiating additional tranches of funding in good faith; however, no definitive agreements are currently in place.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results and performance, which are subject to substantial risks and uncertainties that could cause actual results to differ materially.
- Regulatory Compliance: The securities issued under the Letter Agreement were exempt from registration pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b).
Investor Verification Checklist
- Verify the final closing date and receipt of the $1,500,000 funding tranche from 3i, LP.
- Monitor the Board's decision on the specific reverse stock split ratio (1-for-5 to 1-for-50) within the next 12 months.
- Review the interim financial impact of the 5% royalty agreement on Velocity Bioworks, Inc. gross revenue.
- Confirm the appointment of a permanent Chief Executive Officer to replace Michael K. Handley.
- Check for any amendments to this 8-K regarding final voting results if preliminary counts change.